NK-based Immunotherapy for glioblastoma using injectable hydrogel under MRI guidance.

GBM is one of the most devastating tumor because of its low survival rate. GBM is highly resistance to chemotherapy and radiotherapy and is also “protected” by the BBB, making the choice of immunotherapy is very limited. Although adoptive transfer of NK or genetic modified CAR-NK cells have been shown to be one of the promising approach in GBM, its efficacy is greatly hindered by the presence of BBB, the abnormal tumor microenvironment and the suppressive immune environment in the CNS. A new delivery approach should be developed to protect NK cells to improve the efficacy of NK-based immunotherapy.